~~<i id='F0503EB0BE'><strike id='F0503EB0BE'><tt id='F0503EB0BE'><pre id='F0503EB0BE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

comprehensive

author：fashion 2025-09-29 01:08:25 - browse：89

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Antibiotic resistance and the global rise in human conflict

entertainment

focus

leisure time

knowledge

leisure time

entertainment

MollyFergusonforSTATIfyou’readrugcompanyexecutive,youprobablyfeellikeyougotuponthewrongsideofbed.OnT

WSS

Amylyx ALS drug failure raises questions and concerns

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

UCB departs biotech trade group BIO

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

A deep dive into Applied Therapeutics’ data, and questions on Cassava

A single drug, study failures leave Anavex with nothing but cash

entertainment

comprehensive

entertainment

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Hepatitis C has a cure — but many Americans still lack access to it

The drug industry has found itself all alone in Washington

How one medical school became remarkably diverse

Morgan Health, with ambitious aims, wants you to know it’s still here

State Dept. review finds Biden bears some blame for Afghanistan failures

Just how do doctors, lawmakers, and the public define abortion?

Apple is now the first public company to be valued at $3 trillion

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

focus

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

JPM: CVS says Medicare Advantage patients are impacting profits

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

The Readout: Amylyx, Alumis, and Lundbeck drug updates

What it’s like to watch children die of measles

leisure time

knowledge

leisure time

entertainment